Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$194.14 USD

194.14
3,179,012

-1.31 (-0.67%)

Updated Oct 4, 2024 03:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Apple, Amazon, AbbVie, Philip Morris International and BlackRock

by Zacks Equity Research

Apple, Amazon, AbbVie, Philip Morris International and BlackRock are included in this Analyst Blog.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session.

Mark Vickery headshot

Top Analyst Reports for Apple, Amazon.com & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and AbbVie Inc. (ABBV).

The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca

by Zacks Equity Research

AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as Fundamentals Stay Strong

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FDL

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $142.24, moving +0.58% from the previous trading session.

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

by Zacks Equity Research

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

by Zacks Equity Research

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

by Zacks Equity Research

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

by Zacks Equity Research

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

    AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

    by Zacks Equity Research

    Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

    The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

    by Zacks Equity Research

    Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.

    Kinjel Shah headshot

    Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates

    by Kinjel Shah

    Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.

    Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

    by Zacks Equity Research

    Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

    AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids

    by Zacks Equity Research

    AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients

    Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study

    by Zacks Equity Research

    Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.

    Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain

    by Zacks Equity Research

    The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.

    The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar

    by Zacks Equity Research

    JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar are included in this Analyst Blog.

    Sheraz Mian headshot

    Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott

    by Sheraz Mian

    Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT).

    I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal

    by Zacks Equity Research

    I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.

    Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.